J&J Gets CHMP Positive Option for Preventive Ebola Vaccine Regimen
By Colin Kellaher
Johnson & Johnson on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use recommended
approval of its investigational Ebola vaccine regimen for the
prevention of the disease caused by the Zaire ebolavirus
J&J said the two-dose regimen is designed to support
preventive vaccination in countries that are at risk of Ebola
outbreaks, as well as for other at-risk groups, such as healthcare
and lab workers.
The company said the regimen includes Ad26.ZEBOV as the first
dose, based on its Janssen Pharmaceutical Cos. unit's proprietary
AdVac viral vector technology, and MVA-BN-Filo as the second dose,
based on Bavarian Nordic A/S's MVA-BN technology, administered
roughly eight weeks later.
"Today's CHMP opinion confirms the potential of Janssen's
vaccine technology, which we hope to apply against a range of
established and emerging epidemic threats, including the Covid-19
pandemic," J&J said.
The regimen now awaits approval from the European Commission,
which generally follows the CHMP's recommendations.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
May 29, 2020 07:53 ET (11:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.